MedTrace Logo

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043

NCT00984880 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2009-12-18

No results posted yet for this study

Summary

The primary purpose of this study is to assess the safety and tolerability of AZD3043 following administration of single ascending bolus doses (Part A) and single ascending bolus doses followed by infusion (Part B).

Conditions

  • Healthy

Interventions

DRUG

AZD3043

Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)

Sponsors & Collaborators

Principal Investigators

  • Johan Wemer · AstraZeneca

  • Sigridur Kalman · Karolinska University Hospital

  • Stephen Kanes · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Completion
2009-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00984880 on ClinicalTrials.gov